Clinical efficacy and prognostic factors of CT-guided 125I brachytherapy for the palliative treatment of retroperitoneal metastatic lymph nodes

Table 3 Univariate analysis of LTPFS

	P
Gender (Male)	0.137
Age(<60)	0.418
Primary tumor^a	0.069
Hepatic cance	0.217
Ovarian cancer	0.003
Cervical cancer	0.845
Colorectal cancer	0.962
Others*
Other metastases^*	0.140
Abnormal tumor Markers	0.636
Number^b	0.520
1	0.758
2	0.147
≥ 3
Maximum diameter^c	<0.001
≤ 3 cm	<0.001
3-5 cm	0.004
≥ 5 cm
Chemo ≥10*	0.620
Previous Radio*	0.017
Postoperative metastasis	0.999
D90 ≥ 120Gy	0.687
Uniform density^#	0.009
Necrosis^#	<0.001
Regular morphology ^#	0.002
Fusion^#	0.003
Clear boundaries^#	0.011
Invasion of vessels visible on image^#	<0.001
Significant enhancement^#	0.107
Location^d	0.098
Anterior renal vein^#
Posterior renal vein^#
OAR<3*	0.020
Patients’ position^e	0.766
Supine	0.433
Prone	0.534
Lateral position
Puncture path^f	0.003
Hepatic approach	0.014
Abdominal wall	0.072
Paravertebral approach

^{a, b, c, d, e f}the last variable as a reference; Others * Including renal cancer, esophageal cancer, nasopharyngeal cancer, gastric cancer, pancreatic cancer, duodenal cancer, ampullary carcinoma, endometrial cancer, bladder cancer, testicular cancer, ureteral cancer, renal pelvic carcinoma, lung cancer, embryo cancer; other metastases *, Refers to metastasis with other sites in addition to retroperitoneal lymph nodes before the treatment of ¹²⁵I brachytherapy; Chemo *, Chemotherapy; Radio *, Radiotherapy; *OAR, The organs at risk; ^# The assessment of image feature was mainly completed by two radiologists(> 10 years of experiences in imaging diagnosis) in our center. When the Initially evaluation results were inconsistent, need to reach an agreement after negotiation

ISSN: 1470-7330